Achieve Life Sciences, Inc. (DUS:SP4P) Financings

Achieve Life Sciences, Inc.

Financings

RaiseDate
Private placement of securities and milestone warrants
Update: US$180M–US$354M
Use of proceeds: Development and launch of cytisinicline, if approved, for nicotine dependence
Apr 16, 2026
Public offering of common stock and accompanying common warrants
Closed: US$45M raised · US$3 a share · Warrants at US$3 for 60 months · Citizens Capital Markets +2
Dealers: Citizens Capital Markets (co-lead), Raymond James (co-lead), Lake Street Capital Markets, LLC
Use of proceeds: Advance cytisinicline through potential FDA marketing approval, plus working capital and general corporate purposes
Jun 30, 2025

Read by 6ix AI from the company's releases